clotrimazole has been researched along with Neoplasms in 19 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral clotrimazole is an effective agent for prophylaxis of oropharyngeal candidiasis in susceptible cancer patients." | 6.66 | Prophylaxis of oropharyngeal candidiasis with clotrimazole. ( Alvarado, T; Bodey, GP; Fainstein, V; Yeo, E, 1985) |
| "Oral clotrimazole is an effective agent for prophylaxis of oropharyngeal candidiasis in susceptible cancer patients." | 2.66 | Prophylaxis of oropharyngeal candidiasis with clotrimazole. ( Alvarado, T; Bodey, GP; Fainstein, V; Yeo, E, 1985) |
| "Patients with malignant neoplasms who were receiving chemotherapy and renal transplant recipients who were receiving immunosuppressives were randomized to receive either clotrimazole (10 mg) or placebo troches three times a day in a prospective, double-blinded study." | 2.65 | Prophylaxis of oral candidiasis with clotrimazole troches. ( Dekker, PT; Nightingale, CH; Owens, NJ; Quintiliani, R; Schauer, PK; Schweizer, RT, 1984) |
| "Treatment of cancer is increasingly effective but is associated with short and long term side effects." | 2.44 | Interventions for treating oral candidiasis for patients with cancer receiving treatment. ( Clarkson, JE; Eden, OB; Worthington, HV, 2007) |
| "Treatment of cancer is increasingly effective but is associated with short and long-term side effects." | 2.42 | Interventions for treating oral candidiasis for patients with cancer receiving treatment. ( Clarkson, JE; Eden, OB; Worthington, HV, 2004) |
| "Treatment of cancer is increasingly effective but is associated with short and long-term side effects." | 2.41 | Interventions for treating oral candidiasis for patients with cancer receiving treatment. ( Clarkson, JE; Eden, OB; Worthington, HV, 2002) |
| "A549 lung cancer cells or HCT-116 cells deficient in Bak and Bax were also resistant to apoptosis with the combination implicating the intrinsic apoptotic pathway." | 1.51 | Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models. ( Bates, SE; Curt, KM; Gottesman, MM; Kozlowski, H; McDonald, AJ; Patel, RP; Robey, RW; Sackett, DL, 2019) |
| "Diarrhea is a major side effect of ErbB receptor tyrosine kinase inhibitors (TKIs) in cancer chemotherapy." | 1.51 | Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea. ( Cil, O; Duan, T; Thiagarajah, JR; Verkman, AS, 2019) |
| "Clotrimazole (CTZ) has been proposed as an antitumoral agent because of its properties that inhibit glycolytic enzymes and detach them from the cytoskeleton." | 1.42 | Phosphatidylinositol-3-kinase as a putative target for anticancer action of clotrimazole. ( Carvalho, RS; Furtado, CM; Marcondes, MC; Sola-Penna, M; Zancan, P, 2015) |
| "Ketoconazole (KTZ) has been used as a second-line agent in hormone-refractory cancer therapy." | 1.32 | Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor. ( Anzellotti, A; Rieber, M; Sánchez-Delgado, RA; Strasberg Rieber, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Mayer, CD | 1 |
| Bracher, F | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Cherukupalli, S | 1 |
| Hampannavar, GA | 1 |
| Chinnam, S | 1 |
| Chandrasekaran, B | 1 |
| Sayyad, N | 1 |
| Kayamba, F | 1 |
| Reddy Aleti, R | 1 |
| Karpoormath, R | 1 |
| Huryn, DM | 1 |
| Kornfilt, DJP | 1 |
| Wipf, P | 1 |
| Peterková, L | 1 |
| Kmoníčková, E | 1 |
| Ruml, T | 1 |
| Rimpelová, S | 1 |
| da Silva Dos Reis Condé, CA | 1 |
| de Andrade Querino, AL | 1 |
| Silva, H | 1 |
| Navarro, M | 1 |
| McDonald, AJ | 1 |
| Curt, KM | 1 |
| Patel, RP | 1 |
| Kozlowski, H | 1 |
| Sackett, DL | 1 |
| Robey, RW | 1 |
| Gottesman, MM | 1 |
| Bates, SE | 1 |
| Duan, T | 1 |
| Cil, O | 1 |
| Thiagarajah, JR | 1 |
| Verkman, AS | 1 |
| Furtado, CM | 1 |
| Marcondes, MC | 1 |
| Carvalho, RS | 1 |
| Sola-Penna, M | 1 |
| Zancan, P | 1 |
| Clarkson, JE | 3 |
| Worthington, HV | 3 |
| Eden, OB | 3 |
| Strasberg Rieber, M | 1 |
| Anzellotti, A | 1 |
| Sánchez-Delgado, RA | 1 |
| Rieber, M | 1 |
| Sheklakov, ND | 1 |
| Rukavishnikova, VM | 1 |
| Quintiliani, R | 2 |
| Owens, NJ | 2 |
| Quercia, RA | 1 |
| Klimek, JJ | 1 |
| Nightingale, CH | 2 |
| Shechtman, LB | 1 |
| Funaro, L | 1 |
| Robin, T | 1 |
| Bottone, EJ | 1 |
| Cuttner, J | 1 |
| Schweizer, RT | 1 |
| Schauer, PK | 1 |
| Dekker, PT | 1 |
| Yeo, E | 1 |
| Alvarado, T | 1 |
| Fainstein, V | 1 |
| Bodey, GP | 1 |
8 reviews available for clotrimazole and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
Topics: Adenosine; Anti-Infective Agents; Antineoplastic Agents; Cytokinins; Enzyme Inhibitors; Humans; Mole | 2018 |
p97: An Emerging Target for Cancer, Neurodegenerative Diseases, and Viral Infections.
Topics: Acetanilides; Animals; Benzothiazoles; Drug Delivery Systems; Endoplasmic Reticulum; Humans; Neoplas | 2020 |
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Gene Regulatory Networks; Humans; Neoplasms; Prot | 2020 |
Interventions for treating oral candidiasis for patients with cancer receiving treatment.
Topics: Antifungal Agents; Candidiasis, Oral; Clotrimazole; Humans; Ketoconazole; Neoplasms; Randomized Cont | 2004 |
Interventions for treating oral candidiasis for patients with cancer receiving treatment.
Topics: Antifungal Agents; Candidiasis, Oral; Clotrimazole; Humans; Ketoconazole; Neoplasms; Randomized Cont | 2007 |
[Imidazole preparations in mycology].
Topics: Animals; Antifungal Agents; Candidiasis; Clotrimazole; Coccidioidomycosis; Cryptococcosis; Dermatomy | 1984 |
Interventions for treating oral candidiasis for patients with cancer receiving treatment.
Topics: Antifungal Agents; Candidiasis, Oral; Clotrimazole; Humans; Ketoconazole; Neoplasms; Randomized Cont | 2002 |
4 trials available for clotrimazole and Neoplasms
| Article | Year |
|---|---|
Treatment and prevention of oropharyngeal candidiasis.
Topics: Adolescent; Adult; Aged; Aspergillosis; Candidiasis; Child; Child, Preschool; Clinical Trials as Top | 1984 |
Clotrimazole treatment of oral candidiasis in patients with neoplastic disease.
Topics: Candidiasis, Oral; Clinical Trials as Topic; Clotrimazole; Double-Blind Method; Esophagitis; Humans; | 1984 |
Prophylaxis of oral candidiasis with clotrimazole troches.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Candidiasis, Oral; Clinical Trials as Topic; Clo | 1984 |
Prophylaxis of oropharyngeal candidiasis with clotrimazole.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Candidiasis; Candidiasis, Oral; Clotrimazole; Diseas | 1985 |
7 other studies available for clotrimazole and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferatio | 2011 |
Silver(I) complexes containing N-heterocyclic carbene azole drugs: Synthesis, characterization, cytotoxic activity, and their BSA interactions.
Topics: Animals; Antineoplastic Agents; Azoles; Clotrimazole; Coordination Complexes; Humans; Ketoconazole; | 2023 |
Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Clotrimazole; Depsipeptides; Drug Synergism; HCT116 Ce | 2019 |
Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.
Topics: Acetamides; Afatinib; Animals; Cell Membrane Permeability; Clotrimazole; Colon; Cystic Fibrosis Tran | 2019 |
Phosphatidylinositol-3-kinase as a putative target for anticancer action of clotrimazole.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Division; Cell Survival; Clotrimazole; Energy Meta | 2015 |
Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous | 2004 |